ANDREA GOULBOURNE-SMITH: Open Payments
NPI 1003397944 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 36 payments from 11 companies in 2025. Trend: 2023 $1,090 · 2024 $641 · 2025 $882
Food & beverage: $882
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $232 |
| Indivior Inc. | 6 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Janssen Pharmaceuticals, Inc | 2 | $61 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Almatica Pharma LLC | 2 | $34 |
| Braeburn Inc. | 1 | $23 |
Products named: INGREZZA, SUBLOCADE, TRINTELLIX, CAPLYTA, INVEGA SUSTENNA, UZEDY, Auvelity, LOREEV XR.
Industry payments across FL — which companies pay providers there.
